HDClarity

A Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development

for Huntington’s Disease

Find this study on clinicaltrials.gov and the enroll-hd website.

Sponsor	University College London / CHDI Foundation
The Study	A longitudinal open-ended observational study that builds on data from Enroll-HD to evaluate biomarkers (characteristics of the body that can be measured) in cerebrospinal fluid (CSF) of people with HD.
Main Goals	Identify and validate biomarkers to track disease progression, and response to treatment
Who can participate?	• Enroll-HD participants ages 18 - 75 with a known HD gene status, or control participants • Juvenile HD participants ages ≥ 11
What is required of participants?	• Screening process to ensure eligibility • Participation in Enroll-HD • Cerebrospinal fluid (CSF) up to 20 ml via lumbar puncture • Blood sample of approximately 50 ml
Frequency of Participation	• Two annual visits with screening via blood sample and sampling of cerebrospinal fluid (CSF) • Scheduling can be coordinated with annual Enroll-HD visit
Contact	Rithica Deepak at [email protected] or (713) 500-8121 Brittany Duncan at [email protected] or (713) 486-3134